Yahoo Search Búsqueda en la Web

Resultado de búsqueda

  1. Sir Augustus Frederick d'Este, KCH (13 January 1794 – 28 December 1848) was a relative of the British royal family and the earliest recorded person for whom a definite diagnosis of multiple sclerosis can be made. He was the only son of Prince Augustus Frederick, Duke of Sussex and his wife Lady Augusta Murray.

    • Augustus Frederick Hanover, 13 January 1794, London, Great Britain
    • 28 December 1848 (aged 54), Ramsgate, Kent
  2. Sir Augustus Frederick D’Esté (1794–1848) was an illegitimate royal child, a bachelor, an active member of the Aborigines Protection Society, and the earliest known person diagnosed with multiple sclerosis. For 24 years D’Esté kept a diary, currently held in the Royal College of Physicians’ archives, which documents what he called ‘my case’.

  3. 17 de oct. de 2009 · Abstract. The personal diary of Sir Augustus d’Esté, born 1794 grandson of King George III of England, reveals a medical history strongly suggesting that Augustus suffered from multiple sclerosis (MS). It could well be the first record of a person having this disease.

    • Anne Marie Landtblom, Patrik Fazio, Sten Fredrikson, Enrico Granieri
    • 2010
  4. The first case history of multiple sclerosis: Augustus d’Esté (1794–1848) AbstractThe personal diary of Sir Augustus d’Esté, born 1794 grandson of King George III of England, reveals a medical history strongly suggesting that Augustus suffered from multiple sclerosis (MS).….

  5. The personal diary of Sir Augustus d'Esté, born 1794 grandson of King George III of England, reveals a medical history strongly suggesting that Augustus suffered from multiple sclerosis (MS)....

  6. Abstract. The personal diary of Sir Augustus d’Este ́, born 1794 grandson of King George III of England, reveals a medical history strongly suggesting that Augustus suffered from multiple...

  7. A previously unrecognized case of MS from 1757, long antedating Ollivier and D’Este is presented, noteworthy for the fact that it was associated with a controversial therapeutic trial, presaging the next 21=2 centuries of MS therapeutics.